What's behind GSK's massive earnings and will the stock price surge continue?
Over the past 12 months, Pakistan’s pharmaceutical sector has delivered stellar stock performance
Over the past 12 months, Pakistan’s pharmaceutical sector has delivered stellar stock performance, driven by long-overdue regulatory relief, including significant price hikes in 2023–2024.
This shift came after years of capped prices, surging API costs, and currency depreciation that had severely squeezed margins.
GSK Pakistan, in particular, posted dramatic earnings rebound — from PKR 534 million in 2023 to over PKR 6.5 billion in 2024 — led by improved pricing and margin expansion.
Watch the full video for a comprehensive pharma industry analysis and stock analysis of GSK.
Popular
Spotlight
More from Business
Pakistan to raise petroleum development levy above PKR 100 per liter from July 2025
IMF-backed reforms include carbon levy, debt surcharge removal to tackle energy sector debt
More from Video
Why Karachi's Jinnah Avenue is attracting real estate investors
In this episode of Pakistan Property Playbook, Nukta Correspondent Habib Khan explores the iconic location
Comments
See what people are discussing